Dynavax Technologies Corporation
2929 Seventh Street
Suite 100
Berkeley,
CA 94710-2753
United States - Map
Phone: 510-848-5100
Fax: 510-848-1327
Website: http://www.dynavax.com
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California. Key Statistics
| |
| Dynavax Technologies Corporation’s ISS Governance QuickScore as of May 1, 2013 is 10. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 10; Compensation: 10. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Dr. J. Tyler Martin Sr., M.D.,
53
Pres, Chief Medical Officer and Director | 551.00K | 1.17M | Dr. Dennis A. Carson Ph.D., M.D.,
66
Co-Founder and Director | 44.00K | N/A | Ms. Jennifer Lew ,
40
VP of Fin. and Principal Accounting Officer | 326.00K | 84.00K | Mr. Michael S. Ostrach J.D.,
61
Chief Bus. Officer, Gen. Counsel, VP and Sec. | 484.00K | 313.00K | Dr. Dino Dina M.D.,
66
Consultant and Exec. Director | 607.00K | 701.00K |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.01(0.40%) May 24, 4:00PM EDT|After Hours
:
2.54